American College of Medical Genetics Foundation. 1999. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. Genetics in Medicine.
ACMG Laboratory Practice Committee Working Group. 2000. ACMG recommendations for standards for interpretation of sequence variations. Genetics in Medicine. 2(5): 302-303.
Bhatia, S. et al. 1996. Breast cancer and other second neoplasms after childhood Hodgkin's disease [see comments]. N Engl J Med. 334(12): 745-751.
Bingham, S.A. 1999. "High-meat diets and cancer risk. Proc Nutr Soc. May; 58(2): 243-248.
Boice, J.D. Jr. et al. 1992. Cancer in the contralateral breast after radiotherapy for breast cancer [see comments]. N Engl J Med. 326(12): 781-785.
Breslow, R. and L. Kessler. 1995. Stat bite: knowledge of breast cancer risk by age. J Natl Cancer Institute. 87(1109).
Brinton, L. A. and C. Schairer. 1993. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 15(1): 66-79.
Brinton, L. A. et al. 1988. Menstrual factors and risk of breast cancer. Cancer Invest. 6(3):245-54.
Carter, C. L. et al. 1988. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 128(3): 467-77.
Cannistra, S. A. 2004. Cancer of the ovary. N Engl J Med. 351:2519-2529.
Centers for Disease Control. 2004. Genetic testing for breast and ovarian cancer susceptibility: Evaluating direct-to-consumer marketing --- Atlanta, Denver, Raliegh-Durham and Seattle, 2003. MMWR. 53(27): 603-606
Claus, E.B. et al. 2005. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 293(8): 964-969.
Claus, E. B., et al. J. M. Schildkraut, W. D. Thompson and N. J. Risch. 1996. The genetic attributable risk of breast and ovarian cancer. Cancer. 77(11): 2318-24.
Cleary, M. P. and N. J. Maihle. 1997. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 216(1): 28-43.
Colditz, G. A. 1990. A prospective assessment of moderate alcohol intake and major chronic diseases. Ann Epidemiol. 1(2): 167-177.
Collaborative Group on Hormonal Factors in Breast Cancer. 1997. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet. 350(9084): 1047-1059.
Csokay, B. et al. 1999. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res. Mar 1; 59(5): 995-998.
Cummings, S. R. et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [see comments] [published erratum appears in JAMA 1999 Dec 8;282(22):2124]. JAMA. 281(23): 2189-2197.
Diez, O et al. 2000. BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol. Jan; 11(1): 81-84.
Dupont, W. D. et al. 1994. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 331(1): 10-15.
Fisher, B. et al. 1998. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Jnl Natl Cancer Inst. 90(18): 1371-1388.
Frank, T.S. et al. 2002. Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Jnl Clin Onc. 20(6): 1480-1490.
Friedenreich, C. M. et al. 1998. Epidemiologic issues related to the association between physical activity and breast cancer. Cancer. 83(3 Suppl): 600-610.
Garfinkel, L. et al. 1988. Alcohol and breast cancer: a cohort study. Prev Med. 17(6): 686-693.
Haffty, B.G. et al. 2002. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316): 1471-1477.
Hampel, H. et al. 2004. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 41(2): 81-91.
Hancock, S. L. et al. 1993. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85(1): 25-31.
Hartmann, L. C. et al. 2001. Efficacy of bilateral phophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93(21): 1633-1637.
Hartmann, L. C. et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [see comments]. N Engl J Med. 340(2): 77-84.
Kauff, N.D. et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21): 1609-1615.
Kelsey, J. L. and M. D. Gammon. 1990. Epidemiology of breast cancer. Epidemiol Rev. 12:228-40.
Kerlikowske, K. et al. 1997. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 89(1): 76-82.
King, M. C. et al. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302(5645):643-646.
King, M. C. et al. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bopwel project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286(18):2251-2256.
Longnecker, M. P. et al. 1995. Risk of breast cancer in relation to lifetime alcohol consumption. J Natl Cancer Inst. 87(12): 923-929.
Modan, B. et al. 2001. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA! and BRCA2 mutation. N Engl Jnl Med. 345(4): 235-240.
Narod, S. A. et al. 2002. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 94(23): 1773-1779.
Narod, S. A. et al. 2000. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356(9245): 1876-1881.
Narod, S. A. et al. 1998. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl Jnl Med. 339(7): 424-428.
Prechtel, D et al. 1998. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. Diagn Mol Pathol. Feb; 7(1): 57-62.
Rebbeck, T.R. et al. 2004. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22(6).
Rebbeck, T. R. et al. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346(21) 1616-22.
Reichman, M. E. et al. 1993. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women [see comments]. J Natl Cancer Inst. 85(9): 722-727.
Reis, L.A.G et al. 2000. SEER Cancer Statistics Review, 1973-1997. National Cancer Institute. Bethesda, MD.
Roa, B. B. et al. 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2): 185-187.
Ross, R. K. et al. 2000. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92(4):328-332.
Sankila, R. et al. 1996. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol. 14(5): 1442-1446.
Schairer, C. et al. 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. JAMA. 283(4): 485-491.
Schatzkin, A. et al. 1994. Alcohol and breast cancer. Where are we now and where do we go from here? Cancer. 74(3 Suppl):1101-10.
Schrag, D. et al. 2000. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 283(5): 617-624.
Smith-Warner, S. A. et al. 1998. Alcohol and breast cancer in women: a pooled analysis of cohort studies [see comments]. JAMA. 279(7): 535-540.
Smith, T. J. et al. 1999. American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines. Jnl Clin Onc. 17(3): 1080-1082.
Struewing, J. P. et al. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336(20): 1401-1408.
Trepanier, A. et al. 2004. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. Jnl Gen Counsel. 13(2) 83-112.
Zheng W. et al (1999). N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. Mar; 8(3): 233-239.
References:
American College of Medical Genetics Foundation. 1999. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. Genetics in Medicine.
ACMG Laboratory Practice Committee Working Group. 2000. ACMG recommendations for standards for interpretation of sequence variations. Genetics in Medicine. 2(5): 302-303.
Bhatia, S. et al. 1996. Breast cancer and other second neoplasms after childhood Hodgkin's disease [see comments]. N Engl J Med. 334(12): 745-751.
Bingham, S.A. 1999. "High-meat diets and cancer risk. Proc Nutr Soc. May; 58(2): 243-248.
Boice, J.D. Jr. et al. 1992. Cancer in the contralateral breast after radiotherapy for breast cancer [see comments]. N Engl J Med. 326(12): 781-785.
Breslow, R. and L. Kessler. 1995. Stat bite: knowledge of breast cancer risk by age. J Natl Cancer Institute. 87(1109).
Brinton, L. A. and C. Schairer. 1993. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 15(1): 66-79.
Brinton, L. A. et al. 1988. Menstrual factors and risk of breast cancer. Cancer Invest. 6(3):245-54.
Carter, C. L. et al. 1988. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 128(3): 467-77.
Cannistra, S. A. 2004. Cancer of the ovary. N Engl J Med. 351:2519-2529.
Centers for Disease Control. 2004. Genetic testing for breast and ovarian cancer susceptibility: Evaluating direct-to-consumer marketing --- Atlanta, Denver, Raliegh-Durham and Seattle, 2003. MMWR. 53(27): 603-606
Claus, E.B. et al. 2005. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 293(8): 964-969.
Claus, E. B., et al. J. M. Schildkraut, W. D. Thompson and N. J. Risch. 1996. The genetic attributable risk of breast and ovarian cancer. Cancer. 77(11): 2318-24.
Cleary, M. P. and N. J. Maihle. 1997. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 216(1): 28-43.
Colditz, G. A. 1990. A prospective assessment of moderate alcohol intake and major chronic diseases. Ann Epidemiol. 1(2): 167-177.
Collaborative Group on Hormonal Factors in Breast Cancer. 1997. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet. 350(9084): 1047-1059.
Csokay, B. et al. 1999. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res. Mar 1; 59(5): 995-998.
Cummings, S. R. et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [see comments] [published erratum appears in JAMA 1999 Dec 8;282(22):2124]. JAMA. 281(23): 2189-2197.
Diez, O et al. 2000. BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol. Jan; 11(1): 81-84.
Dupont, W. D. et al. 1994. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 331(1): 10-15.
Fisher, B. et al. 1998. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Jnl Natl Cancer Inst. 90(18): 1371-1388.
Frank, T.S. et al. 2002. Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Jnl Clin Onc. 20(6): 1480-1490.
Friedenreich, C. M. et al. 1998. Epidemiologic issues related to the association between physical activity and breast cancer. Cancer. 83(3 Suppl): 600-610.
Garfinkel, L. et al. 1988. Alcohol and breast cancer: a cohort study. Prev Med. 17(6): 686-693.
Haffty, B.G. et al. 2002. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316): 1471-1477.
Hampel, H. et al. 2004. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 41(2): 81-91.
Hancock, S. L. et al. 1993. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85(1): 25-31.
Hartmann, L. C. et al. 2001. Efficacy of bilateral phophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93(21): 1633-1637.
Hartmann, L. C. et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [see comments]. N Engl J Med. 340(2): 77-84.
Kauff, N.D. et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21): 1609-1615.
Kelsey, J. L. and M. D. Gammon. 1990. Epidemiology of breast cancer. Epidemiol Rev. 12:228-40.
Kerlikowske, K. et al. 1997. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 89(1): 76-82.
King, M. C. et al. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302(5645):643-646.
King, M. C. et al. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bopwel project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286(18):2251-2256.
Longnecker, M. P. et al. 1995. Risk of breast cancer in relation to lifetime alcohol consumption. J Natl Cancer Inst. 87(12): 923-929.
Modan, B. et al. 2001. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA! and BRCA2 mutation. N Engl Jnl Med. 345(4): 235-240.
Narod, S. A. et al. 2002. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 94(23): 1773-1779.
Narod, S. A. et al. 2000. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356(9245): 1876-1881.
Narod, S. A. et al. 1998. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl Jnl Med. 339(7): 424-428.
Prechtel, D et al. 1998. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. Diagn Mol Pathol. Feb; 7(1): 57-62.
Rebbeck, T.R. et al. 2004. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22(6).
Rebbeck, T. R. et al. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346(21) 1616-22.
Reichman, M. E. et al. 1993. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women [see comments]. J Natl Cancer Inst. 85(9): 722-727.
Reis, L.A.G et al. 2000. SEER Cancer Statistics Review, 1973-1997. National Cancer Institute. Bethesda, MD.
Roa, B. B. et al. 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2): 185-187.
Ross, R. K. et al. 2000. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92(4):328-332.
Sankila, R. et al. 1996. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol. 14(5): 1442-1446.
Schairer, C. et al. 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. JAMA. 283(4): 485-491.
Schatzkin, A. et al. 1994. Alcohol and breast cancer. Where are we now and where do we go from here? Cancer. 74(3 Suppl):1101-10.
Schrag, D. et al. 2000. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 283(5): 617-624.
Smith-Warner, S. A. et al. 1998. Alcohol and breast cancer in women: a pooled analysis of cohort studies [see comments]. JAMA. 279(7): 535-540.
Smith, T. J. et al. 1999. American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines. Jnl Clin Onc. 17(3): 1080-1082.
Struewing, J. P. et al. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336(20): 1401-1408.
Trepanier, A. et al. 2004. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. Jnl Gen Counsel. 13(2) 83-112.
Zheng W. et al (1999). N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. Mar; 8(3): 233-239.